Latest From Savara Inc.
Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Nanotechnology, Chips, etc.
- Drug Delivery
- Therapeutic Areas
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Aravas Inc.
- North America
- Parent & Subsidiaries
- Savara Inc.
- Senior Management
Rob Neville, Chmn. & CEO
Dave Lowrance, CFO
Taneli Jouhikainen, MD, PhD, COO
Peter Ginsberg, VP, Bus. Dev.
Cecilia Ganslandt, MD, Head, Medical Affairs
- Contact Info
Phone: (512) 961-1891
6836 Bee Cave Rd., Bldg. 3, Ste. 200
Austin, TX 78746
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.